This article first appeared on GuruFocus .
-
Revenue:Overall revenue grew 20% year-over-year, supported by 18% growth in the conventional market and 26% growth in the US market.
-
US Revenue:Driven by the US subsidiary, with revenues increasing from INR 14.4 crore in the previous year to INR 43.1 crore, a three-fold increase.
-
Gross Margin:Gross margin came in at 59.8%, in line with the company's target, and is expected to remain at a similar level through the year.
-
Operating Expenses:Increased in absolute terms from INR 137 crore to INR 151 crore, but declined as a percentage of revenue from 25.7% to 23.6%.
-
EBITDA Margin:Improved from 37.7% to 38.4%.
-
PBT:Grew by 22.1%, increasing from INR 184.5 crore to INR 223.2 crore.
-
PAT:Stood at INR 179 crore, representing a 19% increase over the previous year.
-
Cash Flow from Operations:Reported at INR 98 crore for the quarter, with the moderation attributed to a conscious decision to increase inventory and receivables.
-
Cash and Cash Equivalents:Increased by INR 266 crore to INR 1,500 crore as of June 2026.
-
Liquid Assets:Increased by 30% (INR 668 crore) from INR 2,207 crore to INR 2,800 crore.
-
Net Worth:Increased by 25% in the last year, or INR 762 crore, from INR 3,013 crore to INR 3,776 crore in June 2026.
-
Warning! GuruFocus has detected 4 Warning Sign with BOM:524742.
-
Is BOM:524742 fairly valued? Test your thesis with our free DCF calculator.
Release Date: August 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Caplin Point Laboratories Ltd ( BOM:524742 ) reported a 20% overall revenue growth, with the US market growing 26% and the emerging markets growing 18%.
-
The company's US injectable business saw a three-fold increase in revenue, from 14.4 crores to 43.1 crores, driven by the US subsidiary.
-
The company maintains a strong balance sheet with free cash reserves of 1,500 crore and total liquid assets of 2,875 crore, with no external bank debt.
-
EBITDA margin improved to 38.4% from 37.7%, driven by a decline in operating expenses as a percentage of revenue from 25.7% to 23.6%.
-
The company is investing in future growth with new manufacturing lines, oncology expansion, API capabilities, and a planned distribution company acquisition in Mexico.
Negative Points
-
Rest of the world (RoW) profitability declined to approximately 33% from 37.5% year-over-year, attributed to increased expenses in generic marketing and expansion into new markets.
-
Cash flow from operations moderated to 98 crores due to a conscious decision to increase inventory by 76 crores and raw material inventory by 15 crores to mitigate supply chain risks.
-
Receivables increased by 46% compared to March, primarily due to government supplies, which are expected to be received only by June 2027.
-
The company faces capacity constraints in its two major factories (CP1 and CSL), limiting its ability to fulfill all current orders.
-
The timeline for new factory completion and product registration transfers could take 1.5 to 3 years, delaying the full revenue contribution from new lines.
Q & A Highlights
Q: What is the outlook for the rest of the world (RoW) profitability, which has been declining quarter-over-quarter, and what is the steady-state level we can expect? A: Chairman C.C. Paarthipan acknowledged the slight decline but attributed it to normal business fluctuations and increased marketing expenses in newer geographies. He reassured that this is not a structural trend and profitability could improve as the company introduces more value-added products. MD Sridhar Ganesan added that the company is performing ahead of its committed contribution margin targets (59.8% vs. 55% target), and quarterly fluctuations depend on product and market mix.
Q: What is the company's strategy for capital allocation, and would management consider investing a portion of its large cash reserves in index funds to improve yields? A: Chairman C.C. Paarthipan stated that the board has discussed moving up the risk curve from ultra-conservative fixed deposits. He acknowledged the suggestion for index funds as a potential next step and noted that capital protection remains paramount. MD Sridhar Ganesan added that the company is also keeping cash available for inorganic opportunities, but a small beginning with index funds could be considered.
Q: Can you provide an update on the plan to acquire a distribution company in Mexico? A: Chairman C.C. Paarthipan confirmed that the company is evaluating three to four potential targets. The acquisition is intended to provide better product selection, customer identification, and market reach. He emphasized that the value of a target depends on whether it distributes local generic products versus multinational brands, with local generic distributors being more valuable to Caplin's model.
Q: What gives management confidence in the utilization of the planned 17 injectable lines, given the significant capacity expansion? A: Chairman C.C. Paarthipan explained that current capacity is insufficient to meet demand, and the new lines will feature advanced automation, isolator technology, and digitization to reduce human intervention. MD Sridhar Ganesan added that the company is booked out until February of next year, has only launched 39 of 60+ ANDAs, has 40+ products in the pipeline, and is expanding into niche areas like blow-fill-seal and inhalation products, all of which will require the new capacity.
Q: As a visionary, how do you define the company's size and position in the next three to four years? A: Chairman C.C. Paarthipan stated that the focus is on building world-class infrastructure across all dosage forms to access regulated markets globally. He highlighted plans for a manufacturing facility in Mexico to gain a 16% price advantage in tenders and a focus on the private market in Latin America. He expressed the ambition to be among the top 20 pharmaceutical companies in India.
Q: What is the timeline for all 17 injectable lines to become operational and start contributing to revenue? A: MD Sridhar Ganesan provided a detailed timeline: the 7th line will start in six to seven months, and five more lines in the new facility (Phase 3) will be operational by this time next year, bringing the total to 13 lines including oncology. The final 3-4 lines will be activated by 2029 and beyond. He also noted that transferring a product from a current line to a new one takes 9-10 months due to post-approval supplement requirements in the US market.
Q: What was the spillover of the El Salvador tender in this quarter, and what can we expect going forward? A: CFO D. Muralidharan clarified that the original El Salvador tender has been fully supplied. However, supplementary tenders are expected to continue, providing additional volumes of 10-15% of the original order. The company is participating in these replenishment tenders, with decisions expected in the coming months.
Q: What is the current and future contribution of Amaris Clinical, and will it offer services to third parties? A: MD Sridhar Ganesan stated that Amaris is primarily a backward integration for the company's internal bioequivalence (BE) studies. With 70 beds expanding to 120, it will cater to internal requirements, reducing study costs by approximately 50% compared to external centers. For the next couple of years, it will remain dedicated to Caplin's own portfolio, including oncology, softgel, and future inhalation products.
Q: Is the company looking at opportunities in the Indian market for distribution or generics? A: Chairman C.C. Paarthipan stated that the company is not looking for a distribution company in India, as generics in India do not offer attractive margins without brand marketing, which is not Caplin's core competence. The focus remains on North and South America, with potential acquisitions in Latin America or the US, where the company can add more value to its existing business.
Q: How is the company preparing for the potential US tariffs on generic pharmaceuticals announced by the Trump administration? A: Chairman C.C. Paarthipan stated that the company will "cross the bridge when we reach there." He noted that tariffs are a global trend toward protecting domestic industries. He suggested that starting a generic factory in the US is not currently cost-effective, but the company will wait and watch, particularly as automation and robotics in manufacturing could eventually make high-cost production locations more viable.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
